Invesco’s Carisma Therapeutics CARM Stock Holding History

Invesco’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,409	Closed	-$91.7K	–	3886
2024 Q1	$91.7K	Buy	40,409 +27,677	+217%	+$66.5K	﹤0.01%	3752
2023 Q4	$37.3K	Buy	12,732 +2,453	+24%	+$7.29K	﹤0.01%	3775
2023 Q3	$43.5K	Hold	10,279	–	–	﹤0.01%	3808
2023 Q2	$90.1K	Buy	+10,279	New	+$56K	﹤0.01%	3745
2022 Q2	–	Sell	-3,590	Closed	-$43K	–	4051
2022 Q1	$43K	Sell	3,590 -4	-0.1%	-$56	﹤0.01%	3942
2021 Q4	$59K	Sell	3,594 -1,351	-27%	-$27.2K	﹤0.01%	3965
2021 Q3	$79K	Buy	4,945 +1,301	+36%	+$62.4K	﹤0.01%	3966
2021 Q2	$337K	Buy	+3,644	New	+$232K	﹤0.01%	3580
2019 Q1	–	Sell	-882	Closed	-$25K	–	3713
2018 Q4	$25K	Sell	882 -27	-3%	-$861	﹤0.01%	3749
2018 Q3	$39K	Sell	909 -27	-3%	-$1.05K	﹤0.01%	3827
2018 Q2	$37K	Buy	+936	New	+$41.2K	﹤0.01%	3811

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco's CARM Position: Q2 2024 in Review

Invesco sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 40,409 shares — an estimated $91.7K sold.

Invesco first reported a position in CARM in Q2 2018 and held it in 11 quarters. The position peaked at $337K in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

Invesco reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
Invesco sold 40,409 Carisma Therapeutics shares in Q2 2024, an estimated $91.7K.
Invesco first reported a position in Carisma Therapeutics in Q2 2018 and held it in 11 quarters.
Invesco's Carisma Therapeutics position peaked at $337K in Q2 2021.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.